GlassScriptPhysician profile
Heather Lehman
NPI 1801096219
$11,382.86
in general payments reported to CMS, 2019-2025
16 companies · $5,997 in 2025
The $5,997 reported for 2025 was more than what 82% of Pediatric Allergy/Immunology providers received nationally (typical 2025 total: $375).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $779 · 2021: $3,090 · 2022: $468 · 2023: $441 · 2024: $608 · 2025: $5,997.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,469 · Food and Beverage: $703 · Honoraria: $650 · Travel and Lodging: $224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,469.00 |
| Food and Beverage | $702.80 |
| Honoraria | $650.00 |
| Travel and Lodging | $223.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $4,049.41 | 2022-2025 | Joenja |
| Chiesi USA, INC. | $3,125.00 | 2021-2024 | Revcovi |
| Genzyme Corporation | $2,373.09 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $525.00 | 2022-2024 | |
| Glaxosmithkline, LLC. | $267.13 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $253.42 | 2019-2025 | Tezspire |
| Genentech USA, INC. | $239.54 | 2019-2024 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $140.09 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $125.00 | 2019 | |
| Csl Behring | $124.99 | 2023 | Hizentra |
| Ars Pharmaceuticals Operations, INC. | $124.89 | 2025 | Neffy |
| Grifols USA, LLC | $18.90 | 2023 | Xembify |
| Sarepta Therapeutics, INC. | $16.40 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Lehman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.